Navigation Links
Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting
Date:5/15/2008

signa is a competitive inhibitor of CYP3A4, CYP2C8, CYP2C9, CYP2D6, and UGT1A1. Since warfarin is metabolized by CYP2C9 and CYP3A4, it should be avoided if possible. Tasigna inhibits human P-glycoprotein. If Tasigna is administered with drugs that are substrates of Pgp, increased concentrations of the substrate are likely and caution should be exercised. Tasigna may also induce CYP2B6, CYP2C8, and CYP2C9. Therefore, Tasigna may alter serum concentration of other drugs.

Food effects: Food increases blood levels of Tasigna. Patients should avoid food 2 hours before and 1 hour after taking dose. Since the capsules contain lactose, Tasigna is not recommended for patients with rare hereditary problems of galactose intolerance, severe lactase deficiency, or of glucose-galactose malabsorption.

Pregnancy: Fetal harm can occur when Tasigna is administered to a pregnant woman. Women should be advised not to become pregnant when taking Tasigna.

Adverse reactions

In chronic phase patients, the most commonly reported adverse reactions ( >10%) were rash (33%), pruritus (29%), nausea (31%), fatigue (28%), headache (31%), constipation (21%), diarrhea (22%), and vomiting (21%). The most common ( >10%) Grade 3/4 adverse reactions were thrombocytopenia (28%), neutropenia (28%), elevated lipase (15%), and hyperglycemia (11%). In accelerated phase patients, the most commonly reported adverse reactions ( >10%) were rash (28%), pruritus (20%), and constipation (18%). The most common ( >10%) Grade 3/4 adverse reactions were thrombocytopenia (37%), neutropenia (37%), anemia (23%), and elevated lipase (17%). Other serious adverse reactions included pneumonia, febrile neutropenia, leukopenia, intracranial hemorrhage, and pyrexia (Grade 3/4: 2%).

Dose adjustments or modifications: Tasigna may need to be temporarily withheld and/or dose reduced for QT prolongation, hematological toxicities that are not related to underlying leukemia, clinically significant mod
'/>"/>

SOURCE Novartis Pharmaceuticals Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Intercell AG to Acquire Iomai Corporation to Expand Late Stage Product Pipeline and Strengthen Leadership in Vaccine Innovation
2. Spirit II Results Support Strength of Boston Scientifics Two Drug-Eluting Stent Platforms
3. BD and PEPFAR Collaborate to Strengthen Laboratory Systems in Fight Against HIV/AIDS and TB
4. Par Pharmaceutical Begins Shipment of Additional Dosage Strength of Generic TOPROL-XL(R)
5. Major Deficiencies in Design; Funding of Clinical Trials Affects Future of Scientific Innovation
6. Inverness Medical Innovations to Present at CIBC World Markets 18th Annual Healthcare Conference on November 7, 2007
7. Abbotts m2000(TM) Molecular Diagnostic Instrument and RealTime HIV-1 Test Win Chicago Innovation Award
8. OrbusNeichs Genous(TM) Bio-Engineered R Stent(TM) is Subject of Sessions on Innovation at TCT 2007
9. StatSure Signs Strategic Financing and License Deals with Inverness Medical Innovations
10. Cleveland Clinic Summits to Focus on Cardiovascular Medical Innovation
11. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2015)... , April 17, 2015  Regulatory leaders in ... released bipartisan discussion draft called "21 st Century ... planned to be taken up by Congress soon and ... and medical device products are developed and marketed in ... reason, many companies have begun to consider how the ...
(Date:4/17/2015)... -- Inivata, a Cambridge, England ... at the 2015 American Association for Cancer Research (AACR) Annual ... Rosenfeld and a poster presentation. Michael Stocum , ... 22 nd . The presentation, entitled Monitoring ... forms part of a session on Recent Advances in ...
(Date:4/17/2015)... April 17, 2015 ASSESS shows ...   is a viable alternative to tumour biopsy   ... all patients with advanced NSCLC   AstraZeneca today ... plasma circulating tumour DNA (ctDNA) testing for epidermal growth factor ... non-small cell lung cancer (NSCLC) in clinical practice. [ ...
Breaking Medicine Technology:21st Century Cures: A Regulatory Game-Changer for the Pharmaceutical Industry 2Inivata Co-founder Nitzan Rosenfeld to Present at AACR Annual Meeting 2"Real World" Data Support Use of Blood Test for EGFR Mutation in Advanced NSCLC 2"Real World" Data Support Use of Blood Test for EGFR Mutation in Advanced NSCLC 3"Real World" Data Support Use of Blood Test for EGFR Mutation in Advanced NSCLC 4
... 2011 SV Life Sciences ("SVLS") today announced the ... SVLS in early 2009 as Venture Partner. ... tremendous experience with large-scale medical technology businesses to our ... Managing Partner. "In doing so, Paul has underscored a ...
... BROOK, N.J., Jan. 6, 2011 The FDA,s nod to ... they have to address the problems of sexual dysfunction. "So ... of Semprae Laboratories, Inc. The announcement of the approval of ... Flibanserin. Dubbed the "pink pill," the female Viagra equivalent, many ...
Cached Medicine Technology:SV Life Sciences Promotes 30-Year MedTech Veteran Paul LaViolette to Partner 2SV Life Sciences Promotes 30-Year MedTech Veteran Paul LaViolette to Partner 3What About Us? The State of Women's Sexual Health in Question 2
(Date:4/18/2015)... Thousand of DePuy Pinnacle hip lawsuits ... who were allegedly harmed by a metal-on-metal version of ... the U.S. District Court, Northern District of Texas. According ... amended an earlier Case Management Order to allow for ... new amendment permits the claims of up to 150 ...
(Date:4/18/2015)... ” was featured on NewsWatch as part of its monthly ... applications on the market for iOS, Android, and ... conducted the app review and shared with viewers how this ... world, people may find themselves in dangerous situations where they ... but some situations can be avoided if there was an ...
(Date:4/17/2015)... York, NY (PRWEB) April 18, 2015 ... at their facility, rounding out their list of diagnostic ... care center for patients on the Upper East Side ... and running at full capacity. The addition of PET-CT, ... gives their physicians the ability to work with patients ...
(Date:4/17/2015)... April 17, 2015 “We have seen healing, ... the past and present,” said Chaplain Shawn Kafader of Friendship ... felt like they had anything to contribute have created beautiful ... overseen a new art therapy program that was launched to ... Masters student from School of the Art Institute in Chicago, ...
(Date:4/17/2015)... Enthusiasts of gourmet cuisine and beverages will be coming ... event will be held in the heart of downtown Grand ... Grand Rapids, MI 49503) and will feature wine personalities and ... encouraged to savor the food and beverage pairings while enjoying ... will feature seven chefs, including:, Chef ...
Breaking Medicine News(10 mins):Health News:DePuy Pinnacle Hip Lawsuits: Federal Litigation Amends Case Management Order to Allow for Joinder of Unrelated Claims 2Health News:DePuy Pinnacle Hip Lawsuits: Federal Litigation Amends Case Management Order to Allow for Joinder of Unrelated Claims 3Health News:A Personal Safety Application was Featured on NewsWatch Television 2Health News:Healing At Friendship Village Due To Art Therapy 2Health News:Children’s Leukemia Foundation of Michigan Presents 3rd Annual CRUSH Grand Rapids 2
... the first to use a new tool to identify the ... of what these microscopic signatures or biomarkers should look like. ... Journal of Proteome Research, the advance could one day lead ... cancer as well as other diseases. , With many diseases, ...
... Provides Interventional Cardiologists with Enhanced ... Faster, More Precise Procedures, CHICAGO, March 31 According ... 1 killer,with an average of one death every 37 seconds. ... contributed to the surge of,Americans with cardiac issues. To address ...
... on Blue Cross ... EAGAN, Minn., March 31 In a peer-reviewed ... Cross and Blue,Shield of Minnesota (Blue Cross) reports that ... visits to the emergency room and,had an 11 percent ...
... medication, study finds , , MONDAY, March 31 (HealthDay News) ... diabetes drug, Amaryl, at slowing clogging of the arteries ... disease. , The Cleveland Clinic researchers behind the new ... diabetes medication has been shown to slow atherosclerosis, giving ...
... 2008 New data from a clinical trial ... patients living with type 2 diabetes, ACTOS® (pioglitazone ... arteries compared to glimepiride, and prevented progression compared ... PERISCOPE (Pioglitazone Effect on Regression of Intravascular Sonographic ...
... Considered by many in medical,marketing to be ... Ferdinand has joined,prominent Houston healthcare and sports marketing ... and Business Development., In her new role ... counsel for existing clients, and develop relationships,with potential ...
Cached Medicine News:Health News:Scientists: New technique identifies molecular 'biomarkers' for disease 2Health News:Scientists: New technique identifies molecular 'biomarkers' for disease 3Health News:See More, Do More: Siemens Highlights New Generation of Interventional Imaging Systems for Cardiology at ACC 2Health News:See More, Do More: Siemens Highlights New Generation of Interventional Imaging Systems for Cardiology at ACC 3Health News:See More, Do More: Siemens Highlights New Generation of Interventional Imaging Systems for Cardiology at ACC 4Health News:Blue Cross' Consumer-directed Health Plan - Options Blue - Members Not Sacrificing Health for the Sake of Saving Money 2Health News:Blue Cross' Consumer-directed Health Plan - Options Blue - Members Not Sacrificing Health for the Sake of Saving Money 3Health News:Diabetes Drug Slows Clogging of Arteries 2Health News:Diabetes Drug Slows Clogging of Arteries 3Health News:New data showed Actos prevented progression of atherosclerotic plaque volume in patients 2Health News:Medical Marketing Veteran Signs on as Director of Strategy and New Business Development at Active Imagination 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: